opicapone
Selected indexed studies
- Opicapone. (, 2012) [PMID:34787988]
- Opicapone for the treatment of Parkinson's disease: a review. (Int J Neurosci, 2023) [PMID:33980110]
- Opicapone for Parkinson's disease. (Aust Prescr, 2023) [PMID:38053568]
_Worker-drafted node — pending editorial review._
Connections
opicapone is a side effect of
Sources
- Opicapone. (2012) pubmed
- Opicapone for the treatment of Parkinson's disease: a review. (2023) pubmed
- Opicapone for Parkinson's disease. (2023) pubmed
- Opicapone: A third generation COMT inhibitor. (2021) pubmed
- Opicapone: A Review in Parkinson's Disease. (2021) pubmed
- Opicapone for Parkinson's disease-related sleep disturbances: The OASIS clinical trial. (2025) pubmed
- Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. (2016) pubmed
- Opicapone as adjunct to levodopa in treated Parkinson's disease without motor complications: A randomized clinical trial. (2025) pubmed
- Opicapone: Once-Daily COMT Inhibitor for the Treatment of Wearing Off in Parkinson's Disease. (2022) pubmed
- Opicapone for the treatment of Parkinson's disease: an update. (2019) pubmed